Indian Express (Free subscription) | 08/13/2008
Fresenius Kabi, a 100% subsidiary of German healthcare group Fresenius, which completed the acquisition process of Dabur Pharma, plans to invest approximately Rs 190 crore over the next two to three years in the API plant of the company.
Hindu (Free subscription) | 08/12/2008
NEW DELHI: Multinational drug firm Fresenius Kabi, which has acquired Dabur Pharma, on Tuesday said it would invest up to 30 million euro in the next 2-3 years in doubling the latter’s active pharmaceutical ingredients manufacturing ...
Daily News Analysis (Free subscription) | 08/12/2008
Multinational drug firm Fresenius Kabi, which acquired Dabur Pharma, is looking to expand the latter's oncology business globally with plans of investing up to 30 million.
Business Wire (Free subscription) | 07/30/2008
BAD HOMBURG, Germany--(BUSINESS WIRE)--Fresenius Medical Care AG & Co. KGaA (NYSE: FMS)(FWB:FME):
Market Watch (Free subscription) | 07/17/2008
TEL AVIV (MarketWatch) -- Fresenius SE, the Bad Homburg, Germany, health-care giant, reported first-half net income rose 8% from the year-earlier period on 2% higher sales. Earnings reached 211 million euros ($333.4 million) for the first half; that figure rose 13% at constant currencies. Salels reached 5.71 billion euros; that's up 9% at constant forex rates. The Fresenius Medical Care...
Business Wire (Free subscription) | 07/17/2008
BAD HOMBURG, Germany--(BUSINESS WIRE)--Fresenius Medical Care AG & Co. KGaA:
Business Wire (Free subscription) | 07/14/2008
WALTHAM, Mass.--(BUSINESS WIRE)--Fresenius Medical Care, operator of the world’s largest provider of dialysis products and services, has been named by The
Seeking Alpha (Free subscription) | 07/10/2008
The M & A Researcher submits: The acquisition of APP Pharmaceuticals, Inc. (APPX) by Fresenius looks to be fairly routine from a regulatory standpoint, as APPX's injectable products compete in an extremely robust market. Its primary competitors are major players such as Bedford, Baxter, Teva, and Hospira, all of which have increased their presence in the injectables market by acquiring APP's...
Postman Patel (Free subscription) | 07/09/2008
German medical group Fresenius (FREG_p.DE: Quote) the biggest worldwide provider of dialysis services have bid a remarkable US$3.7 Bn. for APP Pharmaceuticals (APPX.O: Quote, ) who have, since problems with Chinese supplies of heparin pre cursor, become the dominant US supplier of heparin for dialysis , which hit competitor Baxter International Inc (BAX.N: Quote) The high price saw Fresenius...
Business Wire (Free subscription) | 07/09/2008
BAD HOMBURG, Germany--(BUSINESS WIRE)--Fresenius Medical Care AG & Co. KGaA, the world’s largest provider of dialysis products and services, today
Red Orbit (Free subscription) | 07/09/2008
Luitpold Pharmaceuticals and its subsidiary, American Regent, have entered into a definitive agreement with Fresenius Medical Care for an exclusive US manufacturing and distribution sublicense for Venofer for the end stage renal disease (Stage V) patient population.
Financial Time (Free subscription) | 07/08/2008
Shares in Fresenius dropped more than 9 per cent yesterday after its plans to spend $3.7bn on a US acquisition triggered fears among investors that the German...
Financial Time (Free subscription) | 07/08/2008
Shares in Fresenius plunged more than 9 per cent yesterday after its plans to spend at least $3.7bn on a US acquisition prompted fears the German healthcare group...
PharmaGossip (Free subscription) | 07/07/2008
Fresenius has agreed to buy U.S. generic drug maker APP Pharmaceuticals for $3.7 billion in cash in a deal that will give the German health care company more opportunities in the North American market for drugs administered intravenously. APP Pharmaceuticals may have tipped its hand about its impending sale to German rival Fresenius. The $4.3 billion transaction, which was announced Monday...
Times Online (Free subscription) | 07/07/2008
Fresenius will acquire APP Pharmaceuticals, the US manufacturer of intravenous drugs, for $3.7 billion ($£1.9 billion) in a deal that will help the German dialysis specialist break into the American market.
